Warning: Missing argument 2 for wpdb::prepare(), called in /home4/bquality/public_html/wp-content/plugins/membership/membershipincludes/classes/membershippublic.php on line 2303 and defined in /home4/bquality/public_html/wp-includes/wp-db.php on line 1291

Warning: Missing argument 2 for wpdb::prepare(), called in /home4/bquality/public_html/wp-content/plugins/membership/membershipincludes/classes/membershippublic.php on line 2303 and defined in /home4/bquality/public_html/wp-includes/wp-db.php on line 1291
New Epub on Preclinical Safety Evaluation of Biopharmaceuticals | BioQuality.biz

Thirty years of preclinical safety evaluation of biopharmaceuticals: did scientific progress lead to appropriate regulatory guidance?

Kooijman M, J K van Meer P, H M Moors E, Schellekens H, Expert Opin Drug Saf. 2012 Sep;11(5):797-801. Epub 2012 Aug 6., Utrecht University, Copernicus Institute of Sustainable Development, Innovation studies , Heidelberglaan 2, postbus 80115, 3508 TC, Utrecht , The Netherlands +31 30 253 6771 ; +31 30 251 2746 ; m.kooijman@uu.nl.

Synopsis

  • Due to complexity and other attributes of biopharmaceuticals, it was and is expected that “classical preclinical safety evaluation procedures applied to SMTs would not predict the adverse effects of biopharmaceuticals.” [ed. note: SMT is an abbreviation for Small Molecule Therapeutics]. “Therefore,” the authors go on to say, “until sufficient experience was gained, the preclinical safety evaluation of biopharmaceuticals was carried out on a case-by-case basis.”
  • This Epub reviews the past 30 years, since the first biopharmaceuticals were developed, of preclinical safety experience, and tracks its evolution. Their thoughts, opinions, and conclusions include:
    • Our knowledge has now reached the point that a “preclinical safety evaluation procedure suited to biopharmaceuticals” is now a reasonable hope
    • According to the authors, this experience “shows that, as result of the risk-averse behavior of regulators and industry, classical procedures were taken as starting point although state-of-the-art knowledge on biopharmaceuticals was directed towards creating a new procedure, driven by the specific properties of biopharmaceuticals.”
    • The authors criticize current Regulatory Guidance for the preclinical safety evaluation of biopharmaceuticals because, in their opinion, “it employs a checkbox approach.”
  • They conclude by reminding us that “The adverse effects induced by biopharmaceuticals are on-target or immune system-induced,” and therfore: “the preclinical safety evaluation should not be standardized, but rather driven by product specific safety concerns.”

To see the Abstract, and a link to obtain this paper:  http://www.ncbi.nlm.nih.gov/pubmed/22861668 

Take a look at all the topics we research every month for our Literature Search, our Stories, and our Current Awareness Features, and if you don’t see a topic of major interest to you, send me an email [biotext1ster@gmail.com] or text me @ 951-323-4215 and I will add it if it is appropriate to our editorial scope, which is any topic related to the quality, safety, efficacy, or availability of biopharmaceuticals and biologics. And please support BioQuality by subscribing. See the link at right to go to our Home Page where you will find the subscription link.

Our Current Search Topics:

Access to Medicines

ADME/DMPK  [absorption, distribution, metabolism, and elimination/ drug metabolism and pharmacokinetics]–New! thanks to the reader who suggested this topic

Adverse Event Monitoring and Reporting

Analytical Methods for Characterization and Control

Anti-drug Antibodies and Unwanted Immunogenicity

At the Cutting Edge

Basic Science Relevant to Biopharma and Biologics

Bioanalytical Methods and Issues

Biological Potency, Activity, and other Biological Assays

Biomarkers

Biosimilars, Follow-on Biologics, FOPPs, Biobetters, etc.

Carbohydrate/Glycan/Oligosaccharide/Polysaccharide Characterization and Analysis

Cellular Therapies and Regenerative Medicine

Clinical Issues

Combination Products– New! thanks to the reader who suggested this topic

Container/Closure Issues

Data Analysis, Mathematical Models and Statistics

Development Costs

Development Issues, Concerns, Strategies, etc.

Deviations, Handling and Reporting

Discovery Research

Distribution Issues

European Regulations and Regulatory Perspective

Excipient Analysis and Control

Formulation and Delivery

Gene and other Nucleic Acid Therapy

General Business Issues

GMP Compliance, General

Good Distribution Practice

Host Cell Proteins

Laboratory Issues

Manufacturing and Production Issues

Method Qualification and Validation

Microbial Analysis and Control

Molecular and Personalized Medicine

Nanomedicine and Biopharmaceuticals– New! thanks to the reader who suggested this topic

Nucleic Acids

Particulate Analysis and Issues

Personalized and Molecular Medicine

Preclinical Issues

Process Monitoring, and Control, Process Analytical Technology (PAT)

Process Development

Product Development, Pre-clinical and Clinical

Protein, Glycoprotein, Peptide, and Other Bio-molecule Structure/Function

Proteins, Glycoproteins, Peptides, Antibodies and Other Biomolecules: Characterization, Analysis, and Control

Quality by Design (QbD)

Raw Material Analysis and Control

Regenerative Medicine

Regulations, General Considerations

Regulatory Agencies

Regulatory Submissions, Review, Reporting, etc.

Reference Standard Qualification and Verification

Risk Analysis and Management

Safety and Efficacy Issues

Separation Science

Stability, Aggregation, and Degradation Issues

Surveillance and Pharmacovigilance

Vaccine Development, Testing, Control, Production, Delivery, Stability

Validation

BioQuality, just what you need to know when you need to know it

Comments

Post a comment

You must be logged in to post a comment.

BioQuality.com. Copyright © 2015. All rights reserved.
Turning Information into Practical Knowledge